Version 4 also updates the situation on XMRV research initiatives here in the UK, patient selection criteria for XMRV research studies, testing for XMRV in Europe, and refers to our on-going correspondence with the Chief Medical Officer regarding the safety of blood supplies and blood donation.
The summary is intended to be a balanced account of the current situation. It therefore not only raises questions but is also very cautious when it comes to drawing any firm conclusions at present about the role of XMRV in ME/CFS as either a diagnostic marker, causative agent, or abnormality that requires active treatment with antiviral medication.
Full text available on the home page of the MEA website at: http://www.meassociation.org.uk
NB: XMRV research will be on the agenda when the All Party Parliamentary Group (APPG) on ME meets at the House of Commons on Wednesday 2 December. Department of Health Minister, the Rt Hon Mike O'Brien has agreed to attend this parliamentary meeting, which is open to the public. More information on time, venue, access to the House of Commons etc is contained in our XMRV position statement.
Dr Charles Shepherd
Hon Medical Adviser, MEA